Inclusion Criteria:

- Locally advanced or metastatic NSCLC (stage IIIB or IV)

- Patients who are not candidates for radical combined modality treatments or high-dose
radiation therapy

- At least one measurable lesion according to RECIST criteria

- Good performance status

- Adequate haematological, renal and liver function

- Written informed consent

Exclusion Criteria:

- Previous chemotherapy for NSCLC

- Brain metastasis

- History of cerebral haemorrhage, neurosurgery within 3 previous months or surgery
within the past 6 months

- Indication for anticoagulant therapy, thrombolytic therapy or antiplatelet therapy
for cardiovascular disease

- Concomitant therapy with an anti-angiogenesis agent

- Contra-indication for LMWH

- Life expectancy of < 3 months

- Serious concomitant systemic disease, uncontrolled arterial hypertension, active
peptic ulcer or other condition which does not permit study treatment or follow-up
required to comply with the study protocol